Novel Therapies in Metastatic Castration-Resistant Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 696
Special Issue Editor
Special Issue Information
Dear Colleagues,
Novel therapies in metastatic castration-resistant prostate cancer (mCRPC) offer significant improvement in the treatment of this aggressive form of prostate cancer. These therapies aim to address the challenges posed by tumors that have become resistant to standard hormone therapy. Traditionally, mCRPC was treated with chemotherapy and hormone therapies; however, the disease often progressed despite these interventions. Recently, several novel therapies have emerged.
- Signal transduction inhibitors: Drugs are under development to target novel signal transduction pathways important for prostate cancer cell proliferation, survival, and metastasis.
- Targeted therapies: Progress has been made in directly targeting drugs to prostate cancer cells, for example, via PSMA.
- Immunotherapy: Immune checkpoint inhibitors have shown promise in activating the body's immune system to fight prostate cancer cells.
- Radiopharmaceuticals: Radioactive agents like radium-223 selectively target bone metastases, improving patient quality of life and survival.
- PARP inhibitors: Drugs have demonstrated effectiveness in treating mCRPC patients with certain genetic mutations.
- Biomarker-based approaches: Precision medicine techniques, such as genomic profiling, help identify specific genetic alterations in tumors, allowing for tailored treatment plans.
Novel therapies in metastatic castration-resistant prostate cancer represent a promising frontier in oncology, offering new hope and improved outcomes for patients who were previously faced with limited treatment options. Ongoing research and advancements in personalized medicine continue to shape the landscape of mCRPC treatment.
Dr. Kathryn E. Meier
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- signal transduction inhibitors
- targeted therapies
- immunotherapy
- radiopharmaceuticals
- PARP inhibitors
- biomarker-based approaches
